• News

  #AboardProject

  #ABOARDproject is begonnen! Een bijzondere en nationale samenwerking waarbij meer dan 30 partners, waaronder STIZON, Stichting Informatievoorziening voor Zorg en Onderzoek en wijzelf, PHARMO Institute for Drug Outcomes Research, onze krachten bun...

  New Data Ambulatory Consultations

  NEW DATA available in the PHARMO Database Network – Ambulatory Consultations This new dataset comprises all ambulatory consultations (i.e. out-patient records). This is a great asset for PHARMO, as all specialist visits and out-patient procedure...

  Algoritme coronavirus risico

  Onderzoekers van Amsterdam UMC hebben een algoritme ontwikkeld dat voor patiënten van elke huisartspraktijk het risico berekent om ernstig ziek te worden door het coronavirus. www.amc.nl/web/nieuws-en-verhalen/actueel/actueel/algoritme-berekent-k...

• Events

  Annual Conference International Society for Pharmacoepidemiology

  Annual Conference International Society for Pharmacoepidemiology ICPE All AccessVirtual Event ( September 16-17, 2020) We are pleased to announce that PHARMO will present their study ‘Infliximab Use in the Netherlands: Uptake And Characteristic...

• Vacancy

  (Senior) Research Account Manager

  Wil je bijdragen aan meer transparantie in de gezondheidszorg? Heb je ervaring als onderzoeker en heb je affiniteit met het vertalen van de vragen en onderzoek behoeften van de klant naar een onderzoeksvoorstel/-project?Heb je internationale commerc...

• 

  What we do

  As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  Read more
• 

  What we have

  PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

  Read more

Publications

• Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

  Read more

• No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

  Read more

• Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

  Read more

• The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

  Read more